The ability of the C3d component of complement to enhance antibody responses and protective immunity to influenza virus challenges was evaluated using a DNA vaccine encoding a C3d fusion of the hemagglutinin (HA) from influenza virus. Plasmids were generated that encoded a transmembrane HA (tmHA), a secreted form of HA (sHA), or a sHA fused to three tandem copies of the murine homologue of the C3d (sHA-3C3d). Analysis of the titers, avidity maturation, and hemagglutinin-inhibition activity of raised antibody revealed that immunizations with sHA-3C3d DNA accelerated both the avidity maturation of antibody to HA and the appearance of hemagglutinininhibition activity. These accelerated antibody responses correlated to a more rapid appearance of protective immunity.They also correlated to complete protection from live virus challenge by a single vaccination at a dose ten times lower than the protective dose for non-C3d forms of HA.
One of the challenges faced when developing influenza virus vaccines is the problem of how to protect populations in the face of spreading pandemics. With the advent of air travel, this readily transmitted virus can circumnavigate the globe within days. Each year influenza virus infection causes severe morbidity and even mortality, especially in immunocompromised individuals and the elderly 1 . Protection against influenza virus is primarily mediated by antibodies to the hemagglutinin (HA) glycoprotein, which is responsible for the attachment and penetration of virus into cells during the initial stages of infection [1] [2] [3] . Variation in the HA glycoprotein caused by antigenic drift (mutations within a HA subtype) or antigenic shift (the change to another HA subtype) are responsible for the recurring outbreaks of influenza and poor ability to control these recurring infections by immunization 1, 4 . HAs from different subtypes can have as little as 20% homology in their amino acid sequences. Within strains of a single subtype, the deduced amino acid sequences generally have differences of less than 10% 5 . Thus one solution to the control of emerging influenza infections is to immunize populations rapidly with HAs of the subtype that is currently spreading.
A new approach to the development of influenza vaccines has recently emerged with the advent of DNA use in immunization [6] [7] [8] . Theoretically, cDNA for an emergent virus could be rapidly cloned, introduced into a eukaryotic expression vector, amplified in bacteria and used for protective immunizations. This theoretical scenario has been limited by the reality that DNA-raised antibody responses typically require 2-3 months to reach maximal titers 3 . Compared to protein or attenuated viral vaccines 10, 11 , the slow rise in antibody elicited by DNA vaccines is likely due to the raising of antibody responses by very low levels of antigen 8 . In the race against a pandemic, this relatively long period between immunization and protection could compromise the utility of a DNA-based anti-HA vaccine.
We examined whether a DNA vaccine expressing a fusion of HA and the C3d component of complement could achieve an earlier and more efficient anti-HA B cell response. In previous studies in mice, the fusion The pGA vector contains the cytomegalovirus immediate-early promoter (CMV-IE) plus intron A (IA) for initiating transcription of eukaryotic inserts and bovine growth hormone polyadenylation signal (BGH poly A) for termination of transcription. The vector also contains the Col E1 origin of replication for prokaryotic replication as well as the Kanamycin resistance gene (Kan r ) for selection in antibiotic media.The λ T0 terminator has been placed 3′ to Kan r to increase the stability of eukaryotic inserts. Inserts were cloned into the vector using the Hind III and Bam HI restriction endonuclease sites. (b) Top, the wild-type transmembrane form of the HA protein used as a vaccine insert; middle, secreted form of the HA; bottom, the sHA-3C3d construct used as a vaccine insert. Linkers composed of two repeats of four glycines and a serine (G4S)2 were fused at the junctures of HA and C3d and between each C3d repeat. Rectangles indicate domains. 1, HA1; 2, HA2;TM, transmembrane. of two or three copies of C3d to a model antigen-hen egg lysozymeincreased the efficiency of immunizations by more than 1000-fold 12 .
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In the human immune system, one consequence of complement activation is the covalent attachment of the C3d fragment of the third complement protein to the activating protein. C3d in turn binds to CD21, a molecule with B cell stimulatory functions that amplify B lymphocyte activation, on B lymphocytes 13 . In a HA-C3d fusion protein, the HA moiety of the fusion would bind to anti-HA immunoglobulin receptors on B cells and signal through the B cell receptor, while the C3d moiety of the fusion would bind to CD21 and signal through CD19. According to this hypothesis, a B cell responding to a HA-C3d fusion protein would undergo more effective signaling than a B cell responding to HA alone. Our results demonstrate that mice vaccinated with DNA expressing a secreted HA fused to three copies of C3d-(sHA-3C3d) generated antibody that underwent more rapid avidity maturation than antibody generated by secreted or transmembrane forms of HA. This resulted in more rapid appearance of hemagglutination inhibition (HI) activity and protective immunity.
Results

Expression of plasmids
Three HA plasmids were constructed in the pGA vector to express either the transmembrane form of HA (tmHA), a secreted form of HA (sHA), or sHA-3C3d (Fig. 1) . The tmHA represents the entire cDNA-coding region including the cytoplasmic region. The sHA represents the entire ectodomain of HA including the oligomerization domain but excluding the transmembrane and cytoplasmic region. The sHA-3C3d fusion protein was generated by cloning three tandem repeats of the mouse homologue of C3d 12 in-frame with the gene encoding secreted HA (Fig. 1b) . The proteolytic cleavage sites, found at the junction between each C3d molecule as well as the junction between the HA protein and the first C3d coding region, were destroyed by mutagenesis.
HA was expressed at similar concentrations by plasmids containing either the secreted or transmembrane-associated forms of the antigen, but at a 50% lower concentration by the sHA-C3d-expressing plasmids ( Table 1) . Human 293T cells were transiently transfected with 2 µg of plasmid and both supernatants and cell lysates were assayed for HA using an antigen capture enzyme-linked immunosorbent assay (ELISA). Approximately 80% of the HA protein was secreted into the supernatant for both sHA DNA-and sHA-3C3d DNA-transfected cells ( Table 1) .
As expected, ∼99% of the HA antigen was detected in the lysate of cells transfected with plasmids expressing tmHA ( Table 1 ). The small amount of sHA detected in the cell lysate could have been antigen in the process of transport or sHA that had been reabsorbed onto the cell surface via binding to sialic acid 14 . Western blot analyses revealed sHA, tmHA and sHA-3C3d proteins of expected sizes. Using a polyclonal rabbit antibody to HA, western blot analysis showed a broad band of 65-70 kD corresponding to HA (Fig. 2) . A slightly lower molecular weight band was seen for the sHA molecules. This band size was consistent with truncation of the 33 amino acids corresponding to the transmembrane and cytoplasmic domains of HA (Fig. 2) . A higher molecular weight band at ∼120 kD was consistent with the projected size of the sHA-3C3d fusion protein (Fig. 2) . Strong protein bands were present in the supernatants of cells transfected with sHA DNA or sHA-3C3d DNA, whereas less intense bands were present in the cell lysates. No evidence for the proteolytic cleavage of the sHA-C3d fusion protein was seen by western analysis. As expected, a strong band was present in lysates from cells transfected with tmHA DNA and no protein was detected in the supernatant from these same transfected cells.
Antibody response to HA DNA immunizations
The tmHA-and sHA-3C3d-expressing DNA plasmids raised higher titers of ELISA antibody than the sHA DNA-expressing plasmids. BALB/c mice were vaccinated with DNA-coated gold particles via gene gun with a 0.1 µg or 1 µg inoculum. Four weeks after vaccination half of the mice in each group were boosted with an identical dose of DNA to that initially given. Total anti-HA IgG induced by the sHA-3C3d-and tmHA-expressing plasmids were similar in the different experimental mouse groups and three to fivefold higher than the amount raised by the sHA-expressing plasmids ( Fig. 3a-d ). In addition, the amount of anti-HA elicited increased relative to DNA used for vaccination, in a dose-dependent manner (Fig 3e,f) . Overall, the dose response curves and temporal pattern for the appearance of anti-HA were similar in the mice vaccinated with tmHA DNA or sHA-3C3d DNA, but lower and slower in the mice vaccinated with sHA DNA. As expected, the booster immunization both accelerated and increased the titers of anti-HA.
Avidity of mouse HA antiserum
Sodium thiocyanate (NaSCN)-displacement ELISA demonstrated that the avidity of the HA-specific antibody generated with sHA3C3d-expressing DNA was consistently higher than antibodies from sHA DNA-or tmHA DNA-vaccinated mice (Fig. 4) . The avidities of specific antibodies to HA were compared by using graded concentrations NaSCN, a chaotropic agent, to disrupt antigen-antibody interactions 15 . The binding of antibodies with less avidity to the antigen is disrupted at lower concentrations of NaSCN than that of antibodies with greater avidity to the antigen. The effective concentration of NaSCN required to release 50% of antiserum (ED50) collected at 8 weeks after vaccination from sHA DNA-or tmHA DNA-boosted mice (0.1 µg or 1 µg) was ∼1.20 M (Fig. 4a) . In contrast, antiserum from mice vaccinated and boosted with sHA3C3d DNA had an ED50 of ∼1.75 M (Fig. 4b) . At the time of challenge (14 weeks after vaccination), the ED50 had increased to ∼1.8 M for antibodies from both sHA DNA-and tmHA DNA-vaccinated mice (Fig. 4c) . Antibodies from mice vaccinated with sHA3C3d DNA had increased to an ED50 of ∼2.0 M (Fig 4d) . These results suggest that the antibody from sHA-3C3d DNA-vaccinated mice had undergone more rapid affinity maturation than antibody from either sHA DNA-or tmHA DNA-vaccinated mice. The difference between the temporal avidity maturation of antibody for sHA-3C3d and tmHA was independent of the level of the raised antibody. Both of these plasmids had similar temporal patterns for the appearance of antibody and dose response curves for the ability to raise antibody (Fig. 3) .
HA-inhibition titers
HI assays were performed to evaluate the ability of the raised antibody to block binding of A/PR/8/34 (H1N1) to sialic acid. The HI titers in serum samples collected from mice 8 and 14 weeks after vaccination were measured. All boosted mice had measurable HI titers at week 14 regardless of the dose or vaccine given (Fig. 5) . The highest titers (up to 1:5280) were recorded for the sHA-3C3d DNA-vaccinated mice. Nonboosted mice showed more variation in HI titers (Fig. 5) . Nonboosted mice vaccinated with a 0.1 µg dose of either sHA DNAor tmHA DNA-expressing plasmids had low HI titers of 1:10. In contrast, mice vaccinated with sHA-3C3d DNA had titers greater than 1:640. The only vaccinated mice that had a measurable HI titer (1:160) at week 8 were boosted mice vaccinated with a 1 µg dose sHA-3C3d DNA. These results indicate that C3d, when fused to sHA, is able to stimulate specific B cells to increase the avidity maturation of antibody and thus the production of neutralizing antibodies to HA.
Protective efficacy to influenza challenge
Consistent with eliciting the highest titers of HI antibody, the sHA-3C3d DNA raised more effective protection than the sHA or tmHA DNAs. To test the protective efficacy of the various HA-DNA vaccines, mice were challenged with a lethal dose of A/PR/8/34 influenza virus (H1N1) and monitored daily for morbidity (as measured by weight loss) and mortality. Weight loss for each animal was plotted as a percentage of the average weight before challenge versus days after challenge (Fig. 6) . Viruschallenged naïve mice and pGA vector only-vaccinated mice showed rapid weight loss, with all the mice losing >20% of their body weight by 8 days after challenge (Fig. 6) . In contrast, PBS buffer mock-challenged mice showed no weight loss over the 14 days of observation. All boosted mice survived challenge, 14 weeks after vaccination, regardless of the dose of DNA plasmid administered. However, boosted mice vaccinated with a 0.1 µg dose of sHA DNA did drop to 92% of their initial body weight at 8 days after challenge before recovering (Fig. 6d) . In contrast when 1 µg-dose-boosted mice were challenged 8 weeks after vaccination, the only mice to survive challenge were sHA-3C3d DNAand tmHA DNA-vaccinated mice, albiet with greater weight loss than was observed from mice challenged 14 weeks after vaccination. The only 0.1 µg-dose-boosted mice to survive challenge 8 weeks after vaccination were the sHA-3C3d-vaccinated mice (Fig. 6b) .
Among the nonboosted 0.1 µg-dose immunizations, only the sHA3C3d DNA-vaccinated mice survived challenge at 14 weeks after vaccination (Fig. 6f) . All mice administered a single DNA vaccination lost weight. However, of these, the sHA-3C3d DNA-vaccinated mice lost the least weight and these mice were the only mice to survive the lethal challenge (Fig. 6 ). These results demonstrate the that 3C3d protein, when fused to HA, increased the efficiency of a DNA vaccine allowing for a reduction in dose of DNA and the number of vaccinations needed to afford protection to a lethal influenza virus challenge.
Discussion
The most likely mechanism by which C3d serves as an adjuvant for sHA is the binding of C3d to CD21 on the surface of B cells. CD21 and CD19 have been shown to activate B cells after receptor interaction 13, 16 . C3d could act by one or more different mechanisms that include directly stimulating antibody-producing B cells or by providing antigen depots on follicular dendritic cells. One hypothesis for the induction of increased antibody responses by C3d is that C3d fusion proteins stimulate and expand the pool of anti-HA-specific B cells. The sHA-3C3d fusion protein allows for a cross-linking of HA-specific cell surface immunoglobulin and CD21, thereby leading to the expansion of B cells specific for HA and not just a generic stimulation of all B cells by nonfused C3d. A second hypothesis is that the fused C3d facilitates binding of the HA antigen to the follicular dendritic cells in germinal centers where affinity maturation occurs 17, 18 . Once the HA is trapped in the germinal center it can both attract and stimulate affinity maturation in responding B cells. A role for complement receptors, such as CD21, has been shown to be important in responses of the B cells to protein antigens within germinal centers 19 . C3d could operate by either of these methods.
One of the more interesting features of the antibody raised by sHA3C3d DNA was its avidity maturation. Avidity is a term used to describe the strength of interaction between multivalent antigens and antibodies in serum and is dependent on the individual affinities of the polyclonal antibodies in question 20 . After immunization, strong proliferation of B cells occurs in the follicles of peripheral lymphatic tissues leading to the formation of germinal centers. Within germinal centers, diversification of B cells, predominately by somatic hypermutations, results in a large repertoire of antigen-specific B cells with high affinity B cell receptors 17, 18 . Eight weeks after vaccination, the avidity of the antibody to HA in boosted mice was stronger in sera from mice inoculated with sHA3C3d than in sera from sHA DNA-or tmHA DNA-inoculated mice. By 14 weeks after vaccination, the avidity of the sera from all vaccinated mouse groups was more closely related than was observed at 8 weeks after vaccination. Differences in survival correlated with differences in the amount of HA and HI activity, which in turn correlated with the avidity maturation of antibody. For example, differences in survival of the tmHA-and the sHA-3C3d-vaccinated mice occurred despite the presence of similar ELISA titers of antibody to hemagglutinin. Much effort is being made to improve the efficacy of influenza vaccines. One approach, which was tried in this study, is the use of a C3d fusion protein to reduce the dose and decrease the time to protection of the vaccine. The results demonstrate the effectiveness of C3d-fusions as a molecular adjuvant in enhancing antibody production, enhancing antibody maturation and leading to protective immunity in the influenza mouse model. Using sHA-3C3d DNA, we were able to drop the dose of DNA by 90% compared to wild-type tmHA and achieve both protection and a more rapid onset of protective immunity. This is remarkable in that in vitro, the plasmids expressing sHA-3C3d produced half as much protein as plasmids expressing sHA or tmHA. These results underscore the importance of increasing our understanding of the relationship between innate and acquired immunity. As one of the first molecularly defined adjuvants, C3d could be a major advance in vaccine technology. The results presented demonstrate the applicability of C3d using an antigen from a virus that caused an actual dip in the human population in the 20th century.
Methods
Plasmid DNA. pGA, a eukaryotic expression vector was constructed to contain CMV-IE plus IA for initiating transcription of eukaryotic inserts, and BGH poly A for termination of transcription (Fig 1a) . The vector contains the Col E1 origin of replication for prokaryotic replication and Kan r for selection in antibiotic media. In addition, it contains the λ phage T0 terminator inserted 3′ to Kan r and in the same orientation as Kan r to limit prokaryotic transcriptional elongation into the vaccine insert and increase the stability of eukaryotic inserts during their amplification in bacteria 21 .
Influenza HA sequences from A/PR/8/34 (H1N1) and C3d sequences were cloned into the pGA vaccine vector using unique restriction endonuclease sites (Fig. 1b) . The secreted version was generated by deleting the transmembrane and cytoplasmic domains of HA. This was accomplished using PCR to clone a fragment of the gene encoding HA from the ATG start site to nt1633 22 . The vectors expressing sHA-C3d-fusion proteins were generated by cloning three tandem repeats of the mouse homologue of C3d in-frame with the gene encoding sHA. The construct design was based upon Dempsey et al. and used sequences from pSLG-C3d 12 . Linkers composed of (G4S)2 were fused at the junctures of HA and C3d and between each C3d repeat. Potential proteolytic cleavage sites between the junctions of C3d and the junction of sHA and 3C3d were mutated by using Bam HI and Bgl II fusion to mutate an arginine codon to a glycine codon 12 .
The plasmids were amplified in Escherichia coli strain, DH5α, purified using anionexchange resin columns (Qiagen, Valencia, CA) and stored at -20 °C in dH20. Plasmids were verified by appropriate restriction enzyme digestion and gel electrophoresis. Purity of DNA preparations was determined by optical density reading at 260 nm and 280 nm.
Mice and DNA immunizations. BALB/c mice (Harlan Sprague Dawley, Indianapolis, IN) aged 6-to 8-weeks-old were used for inoculations. Mice, housed in microisolator units and allowed free access to food and water, were cared for under USDA guidelines for laboratory animals. Mice were anesthetized with 0.03-0.04 ml of a mixture of 5 ml ketamine HCl (100 mg/ml) and 1 ml xylazine (20 mg/ml). Gene gun immunizations were performed on shaved abdominal skin using the hand-held Accell gene delivery system as described previously [23] [24] [25] . Mice were immunized with doses containing 0.5 µg of DNA per 0.5 mg of ∼1-µm gold beads (DeGussa-Huls Corp., Ridgefield Park, NJ) at a helium pressure setting of 400 psi.
Transfections and expression analysis. The human embryonic kidney cell line 293T (5 × 10 5 cells per transfection) was transfected with 2 µg of DNA using 12% lipofectamine according to the manufacturer's (Life Technologies, Grand Island, NY) guidelines. Supernatants were collected and stored at -20 °C. Cell lysates were collected in 300 µl of RIPA lysis buffer (0.05M TRIS-HCl, pH 8.0, 0.1% SDS, 1.0% Triton-X-100, 2mM phenylmethylsulfonyl fluoride (PMSF), 0.15 M NaCl) and stored at -20 °C. Quantitative antigen capture ELISAs for HA were conducted as described 20 .
For western hybridization analysis, 15 µl of supernatant or cell lysate was diluted 1:2 in SDS sample buffer (Bio-Rad, Hercules, CA) and loaded onto a 10% SDS-polyacrylamide gel. The resolved proteins were transferred onto a nitrocellulose membrane (Bio-Rad, Hercules, CA) and incubated with a 1:1000 dilution of polyclonal rabbit antibody to HA in PBS buffer containing 0.1% Tween 20 and 1% nonfat dry milk. After extensive washing, bound rabbit antibodies were detected using a 1:2000 dilution of horseradish peroxidase-conjugated goat antibody to rabbit, and enhanced chemiluminescence (Amersham).
ELISA, avidity and HI assays. A quantitative ELISA was performed to assess anti-HA-specific IgG in immune serum using purified influenza virus to coat plates as described 3 . Avidity ELISAs were performed similarly to serum antibody determination ELISAs up to the addition of samples and standards. Samples were diluted to give similar concentrations of IgG. Plates were washed three times with 0.05% PBS-Tween 20 . Different concentrations of the chaotropic agent, sodium thiocyanate (NaSCN) in PBS buffer, were then added (0, 0.5, 1, 1.5, 2, 2.5 and 3 M NaSCN). Plates were allowed to stand at room temperature for 15 min and then washed six times with PBS-Tween 20. Subsequent steps were performed similarly to the serum antibody determination ELISA. The HI assay was performed essentially as described 20 using turkey erythrocytes (Lampiere Biologicals, Pipersville, PA) for agglutination and 4 hemagglutination units of the of A/PR/8/34 (H1N1) virus strain.
Influenza virus challenge.
Challenge with live, mouse-adapted, influenza virus A/PR/8/34 (H1N1) was performed by intranasal instillation of 50 µl allantoic fluid, diluted in PBS buffer to contain three lethal doses of virus, into the nares of ketamine-anesthetized mice 26 . This method leads to rapid lung infections and is lethal to 100% of nonimmunized mice. Individual mice were challenge either 8 or 14 weeks after vaccination and monitored both for weight loss and survival. Data were plotted as the average individual weight in a group, as a percentage of prechallenge weight, versus days after challenge.
